Immuno-oncology Research

Detection of IL21R in human breast cancer using RNAscope 2.5 HD Brown Assay

Detection of IL21R in human breast cancer using RNAscope 2.5 HD Brown Assay

Detection of IL21A in human ovarian cancer using RNAscope 2.5 HD Brown Assay

Detection of IL21A in human ovarian cancer using RNAscope 2.5 HD Brown Assay

Simultaneous detection of CTLA4 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

Simultaneous detection of CTLA4 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

Simultaneous detection of LAG3 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

Simultaneous detection of LAG3 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

Simultaneous detection of PD1 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

Simultaneous detection of PD1 (red) and PD-L1 (green) in NSCLC tissue using RNAScope 2.5 HD Duplex Assay

The field of immuno-oncology (IO) and cancer immunotherapy has expanded rapidly in recent years with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches such as cancer vaccines and chimeric antigen receptor T-cell (CAR-T) therapy.

However, our understanding of the function of immune cells, as well as the interactions of different cell types, in the tumor microenvironment (TME) is still limited. New targets and modulators for cancer therapy in the TME continue to be discovered, yet the tools to investigate these in tumor tissue are often lacking. While immunohistochemistry (IHC) is the conventional method of choice, its use is often limited because of the lack of specific and sensitive antibodies.

The RNAscope® technology enables rapid and efficient detection of co-expression profiles of any target mRNAs, including checkpoint and cell-specific markers, with single-molecule sensitivity and high specificity in formalin-fixed paraffin-embedded (FFPE) tissues.

 

ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment

ACD conducted a study to analyze the co-expression of 8 checkpoint markers in 60 Non-Small Cell Lung Carcinoma FFPE tissues. Figure 1 illustrates an example of co-detection of these markers in a sample. This study reveals a heterogeneous pattern of expression in different tumor tissues as well as intratumor heterogeneity within each tumor and potential insight into combination therapies targeted against different checkpoint pathways. Study data and results are discuss in the webinar accessible below. 

Figure 1: The manual RNAscope® 2.5 HD Duplex assay was used to detect expression of the immune checkpoint markers PD-L1 (green chromogen) and PD-1, PD-L2, CTLA4, LAG3, TIM3 or 4-1BB (red chromogen) in human NSCLC tumor samples. PD-L1 and PD-L2 are primarily expressed in the tumor region and co-expressed in the same tumor cells. CTLA4, 4-1BB, PD1, LAG3, and TIM3 are expressed primarily in the stromal regions. Arrows indicate cells co-expressing PD-L1 with LAG3, TIM3, or PD-L2.

Recorded Webinar

Watch this recorded webinar (June 30th, 2016) to learn more about the ACD study: Surveying expression of immune checkpoint markers in the tissue microenvironment, presented by Jeffrey Kim, Research Scientist at ACD.

Watch Webinar

Poster

Immune profiling the tumor microenvironment with RNA and protein biomarkers by fluorescence multiplex RNA in situ hybridization and immunohistochemistry.

Download Poster

Evaluation of the Expression of Immune Functional Markers in the Tumor Microenvrionment (TME)

Download Poster

Application note

ACD evaluated the performance of the RNAscope® assay in the detection of a wide range of important immuno-oncology markers, including 12 immune checkpoint markers (i.e., PD-L1, CTLA-4, IDO1), 14 immune cell markers (i.e., CD3, CD4, CD8) and 24 immune function markers (i.e., IFNG,TGFB, IL6, CXCL10) in multiple FFPE human tumor samples.

Application Note

Application note "Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope® assay'

Download pdf
 

Appendix

Appendix "Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope® assay"

Download pdf
 
X
Contact Us

Complete one of the two forms below and we will get back to you.

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Advanced Cell Diagnostics , S.r.l.

Via Calabria15
20090 Segrate (Milano) - Italy

Phone: +39.02.95360323
Fax: +39.02.95360992
For European orders: order_europe@acdbio.com

Advanced Cell Diagnostics China

Building 15, No. 26 Xihuan South Road
Beijing Economic-Technological Development Area
Beijing, China, Zip code: 100176

400-966-1796
info_china@acdbio.com
For general information: Leon Li lli@acdbio.com
Web: www.acdbio.com.cn

For general information: info@acdbio.com
For place an order: order@acdbio.com
For product support: support@acdbio.com
For career opportunities: hr@acdbio.com